drugset / Trial / NCT01049815

Sevelamer Hydrochloride and Femoral and Carotid Intima Media Thickness Progression in End Stage Renal Disease

NCT01049815

RandomizedParallel-groupOpen-labelTreatment

Summary

Aims of the multi-center, randomized, treatment-controlled clinical trial are to compare the efficacy of sevelamer hydrochloride to calcium-containing phosphorus binders in reducing the rate of progression of femoral and carotid intimal media thickness (IMT) thickening as measured by B-mode ultrasound in stable maintenance hemodialysis (HD) patients.

Timeline

Start
2005-02
Primary completion
2009-02
Completion
2009-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Calcium carbonate Other / unclassified 600 mg
Subject Sevelamer Other / unclassified 800 mg
Subject Sevelamer Other / unclassified 3200 mg